Sinopharm Group (HKG:1099) booked 1.41 billion yuan in attributable profit for the first quarter of 2026, falling from 1.46 billion yuan in the year-ago period, according to a Hong Kong bourse filing Monday.
Earnings per share were 0.45 yuan, compared with 0.47 yuan in the prior year.
Total operating revenue fell to 140.77 billion yuan from 141.66 billion yuan, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments